FDA’s Zuckerman Supports Idea Of National Percutaneous Valve Registry
This article was originally published in The Gray Sheet
Executive Summary
The development of percutaneous heart valves would benefit from a centralized postmarket registry based on standardized adverse event definitions, according to participants in a recent FDA workshop